Skip to main content

Advertisement

Log in

Recombinant human erythropoietin in the treatment of nonrenal anemia

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Recombinant human erythropoietins (rhEPO) reliably increase hemoglobin levels in cancer patients experiencing chemotherapy-associated anemia. However, in patients with “anemia of cancer” not being treated with chemotherapy, rhEPO appears less effective. Recently, two studies have been broadly discussed which have raised concern on the concomitant use of erythropoietin and chemo- or radiation therapy in cancer patients. In addition, use of rhEPO is generally not considered cost-effective. Thus, the application of rhEPO should be limited to indications with proven clinical benefit. This review will provide an overview of the state of the art use of rhEPO in anemic patients and will discuss future developments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cartwright GE, Wintrobe MM (1952) The anemia of infection. XVII. A review. Adv Intern Med 5:165–226 (abstr)

    PubMed  CAS  Google Scholar 

  2. Bron D, Meuleman N, Mascaux C (2001) Biological basis of anemia. Semin Oncol 28:1–6

    Article  PubMed  CAS  Google Scholar 

  3. Bertero MT, Caligaris-Cappio F (1997) Anemia of chronic disorders in systemic autoimmune diseases. Haematologica 82:375–381

    PubMed  CAS  Google Scholar 

  4. Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689–1692

    Article  PubMed  CAS  Google Scholar 

  5. Spivak JL (1994) Cancer-related anemia: its causes and characteristics. Semin Oncol 21:3–8

    PubMed  CAS  Google Scholar 

  6. Janatpour K, Holland PV (2002) Noninfectious serious hazards of transfusion. Curr Hematol Rep 1:149–155 (abstr)

    PubMed  Google Scholar 

  7. Uhl L (2005) Infectious risks of blood transfusion. Curr Hematol Rep 1:156–162 (abstr)

    Google Scholar 

  8. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100:2303–2320

    Article  PubMed  CAS  Google Scholar 

  9. Wu H, Liu X, Jaenisch R, Lodish HF (1995) Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83:59–67

    Article  PubMed  CAS  Google Scholar 

  10. Anagnostou A, Liu Z, Steiner M et al (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 91:3974–3978

    Article  PubMed  CAS  Google Scholar 

  11. Ribatti D, Presta M, Vacca A et al (1999) Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627–2636

    PubMed  CAS  Google Scholar 

  12. Weber A, Maier RF, Hoffmann U et al (2002) Erythropoietin improves synaptic transmission during and following ischemia in rat hippocampal slice cultures. Brain Res 958:305–311

    Article  PubMed  CAS  Google Scholar 

  13. Celik M, Gokmen N, Erbayraktar S et al (2002) Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 99:2258–2263

    Article  PubMed  CAS  Google Scholar 

  14. Storring PL, Tiplady RJ, Gaines Das RE et al (1998) Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 100:79–89

    Article  PubMed  CAS  Google Scholar 

  15. Ibbotson T, Goa KL (2001) Darbepoetin alfa. Drugs 61:2097–2104

    Article  PubMed  CAS  Google Scholar 

  16. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083–4107

    Article  PubMed  CAS  Google Scholar 

  17. Witzig TE, Silberstein PT, Loprinzi CL et al (2005) Phase III, randomized, double-blind study of epoetin alfa versus placebo in anemic patients with cancer undergoing chemotherapy. J Clin Oncol 23:2606–2617

    Article  PubMed  CAS  Google Scholar 

  18. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ (2004) Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19:898–903

    Article  PubMed  CAS  Google Scholar 

  19. Waltzman R, Williams D (2004) Head-to-head comparison of epoetin alfa (EPO) 40,000 U QW vs. darbepoetin alfa (DARB) 200 μg Q2W in anemic cancer patients receiving chemotherapy (CT): final results of a planned interim analysis (IA). Blood 104 abstract #4233

  20. Glaspy JA, Jadeja JS, Justice G et al (2002) Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 87:268–276

    Article  PubMed  CAS  Google Scholar 

  21. Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB (2003) A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 97:1312–1320

    Article  PubMed  CAS  Google Scholar 

  22. Smith KJ, Bleyer AJ, Little WC, Sane DC (2003) The cardiovascular effects of erythropoietin. Cardiovasc Res 59:538–548

    Article  PubMed  CAS  Google Scholar 

  23. Document. Summary for basis of approval, epoetin alfa (Amgen)

  24. Bohlius J, Langensiepen S, Schwarzer G et al (2004) Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev CD003407

  25. Besarab A, Bolton WK, Browne JK et al (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590

    Article  PubMed  CAS  Google Scholar 

  26. Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459–460

    Article  PubMed  Google Scholar 

  27. Peces R, de la Torre M, Alcazar R, Urra JM (1996) Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 335:523–524

    Article  PubMed  CAS  Google Scholar 

  28. Rossert J, Casadevall N, Eckardt KU (2004) Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 15:398–406

    Article  PubMed  Google Scholar 

  29. Gershon SK, Luksenburg H, Cote TR, Braun MM (2002) Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 346:1584–1586

    Article  PubMed  Google Scholar 

  30. Bennett CL, Luminari S, Nissenson AR et al (2004) Pure red-cell aplasia and epoetin therapy. N Engl J Med 351:1403–1408

    Article  PubMed  CAS  Google Scholar 

  31. Locatelli F, Del Vecchio L (2003) Pure red cell aplasia secondary to treatment with erythropoietin. Artif Organs 27:755–758

    Article  PubMed  Google Scholar 

  32. Schellekens H (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720–1740

    Article  PubMed  CAS  Google Scholar 

  33. Casadevall N, Nataf J, Viron B et al (2002) Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469–475

    Article  PubMed  CAS  Google Scholar 

  34. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt KU, Macdougall IC (2004) Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 363:1768–1771

    Article  PubMed  CAS  Google Scholar 

  35. Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616–1634

    Article  PubMed  CAS  Google Scholar 

  36. Knight K, Wade S, Balducci L (2004) Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 116(Suppl 7A):11S–26S

    Article  PubMed  Google Scholar 

  37. Glaser CM, Millesi W, Kornek GV et al (2001) Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 50:705–715

    Article  PubMed  CAS  Google Scholar 

  38. Seidenfeld J, Piper M, Flamm C et al (2001) Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93:1204–1214

    Article  PubMed  CAS  Google Scholar 

  39. Witzig TE, Silberstein PT, Loprinzi CL et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606–2617

    Article  PubMed  CAS  Google Scholar 

  40. Bokemeyer C, Aapro MS, Courdi A et al (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201–2216

    Article  PubMed  CAS  Google Scholar 

  41. Dammacco F, Castoldi G, Rodjer S (2001) Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 113:172–179

    Article  PubMed  CAS  Google Scholar 

  42. Osterborg A, Brandberg Y, Molostova V et al (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20:2486–2494

    Article  PubMed  CAS  Google Scholar 

  43. Vansteenkiste J, Pirker R, Massuti B et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211–1220

    PubMed  CAS  Google Scholar 

  44. Hedenus M, Adriansson M, San Miguel J et al (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122:394–403

    Article  PubMed  CAS  Google Scholar 

  45. Auerbach M, Ballard H, Trout JR et al (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22:1301–1307

    Article  PubMed  CAS  Google Scholar 

  46. Ganser A (1995) Hematopoietic growth factors in the treatment of the myelodysplastic syndromes. Curr Opin Hematol 2:204–209

    Article  PubMed  CAS  Google Scholar 

  47. Beguin Y (2002) Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 87:1209–1221

    PubMed  CAS  Google Scholar 

  48. Smith RE Jr, Tchekmedyian NS, Chan D et al (2003) A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 88:1851–1858

    Article  PubMed  CAS  Google Scholar 

  49. Abels RI, Larholt KM, Krantz KD, Bryant EC (1996) Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist 1:140–150

    PubMed  CAS  Google Scholar 

  50. Quirt I, Robeson C, Lau CY et al (2001) Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19:4126–4134

    PubMed  CAS  Google Scholar 

  51. Daneryd P, Svanberg E, Korner U et al (1998) Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. Cancer Res 58:5374–5379

    PubMed  CAS  Google Scholar 

  52. Pangalis GA, Siakantaris MP, Angelopoulou MK et al (2002) Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Haematologica 87:500–506

    PubMed  CAS  Google Scholar 

  53. Niscola P, Scaramucci L, Bongarzoni V, Montanero M (2002) Management of disease-related anemia by high-doses of epoetin alfa in patients with multiple myeloma. Blood 100 abstract #5111 (abstr)

  54. Link H, Boogaerts MA, Fauser AA et al (1994) A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 84:3327–3335

    PubMed  CAS  Google Scholar 

  55. Vannucchi AM, Bosi A, Ieri A et al (1996) Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Bone Marrow Transplant 17:527–531

    PubMed  CAS  Google Scholar 

  56. Chao NJ, Schriber JR, Long GD et al (1994) A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin’s and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Blood 83:2823–2828

    PubMed  CAS  Google Scholar 

  57. Ballen KK, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA (2004) Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 22:4087–4094

    Article  PubMed  Google Scholar 

  58. Biggs JC, Atkinson KA, Booker V et al (1995) Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian bone marrow transplant study group. Bone Marrow Transplant 15:129–134

    PubMed  CAS  Google Scholar 

  59. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian cooperative study group for rHuEpo in melodysplastic syndromes. (1998) Br J Haematol 103:1070–1074

    Article  PubMed  Google Scholar 

  60. Terpos E, Mougiou A, Kouraklis A et al (2002) Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 118:174–180

    Article  PubMed  CAS  Google Scholar 

  61. Ganser A, Karthaus M (1997) Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Leuk Lymphoma 26(Suppl 1):13–27

    PubMed  CAS  Google Scholar 

  62. Musto P, Lanza F, Balleari E et al (2005) Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 128:204–209

    Article  PubMed  CAS  Google Scholar 

  63. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L (1995) The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 89:831–837

    Article  PubMed  CAS  Google Scholar 

  64. Negrin RS, Stein R, Doherty K et al (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87:4076–4081

    PubMed  CAS  Google Scholar 

  65. Negrin RS, Stein R, Vardiman J et al (1993) Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82:737–743

    PubMed  CAS  Google Scholar 

  66. Hellstrom-Lindberg E, Ahlgren T, Beguin Y et al (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68–75

    PubMed  CAS  Google Scholar 

  67. Hellstrom-Lindberg E, Negrin R, Stein R et al (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99:344–351

    Article  PubMed  CAS  Google Scholar 

  68. Casadevall N, Durieux P, Dubois S et al (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104:321–327

    Article  PubMed  CAS  Google Scholar 

  69. Jadersten M, Montgomery SM, Dybedal I, Porwit-Macdonald A, Hellstrom-Lindberg E (2005) Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood Epub Apr 19; 0: 200410387

    Google Scholar 

  70. Thompson JA, Gilliland DG, Prchal JT et al (2000) Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS study group. Blood 95:1175–1179

    PubMed  CAS  Google Scholar 

  71. Aloe SM, Latagliata R, Avvisati G et al (1993) Erythropoietin treatment of idiopathic myelofibrosis. Haematologica 78:371–373

    PubMed  Google Scholar 

  72. Tefferi A, Silverstein MN (1994) Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 86:893

    PubMed  CAS  Google Scholar 

  73. Rodriguez JN, Martino ML, Dieguez JC, Prados D (1998) rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach. Haematologica 83:616–621

    PubMed  CAS  Google Scholar 

  74. Mohr B, Herrmann R, Huhn D (1993) Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis. Acta Haematol 90:65–70

    PubMed  CAS  Google Scholar 

  75. Tefferi A (2003) Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new. Semin Hematol 40:18–21

    Article  PubMed  Google Scholar 

  76. Halperin DS, Freedman MH (1989) Diamond-blackfan anemia: etiology, pathophysiology, and treatment. Am J Pediatr Hematol/Oncol 11:380–394

    CAS  Google Scholar 

  77. Niemeyer CM, Baumgarten E, Holldack J et al (1991) Treatment trial with recombinant human erythropoietin in children with congenital hypoplastic anemia. Contrib Nephrol 88:276–280 discussion 281.:276–80

    PubMed  CAS  Google Scholar 

  78. Gillio AP, Faulkner LB, Alter BP et al (1993) Successful treatment of Diamond–Blackfan anemia with interleukin 3. Stem Cells 11(Suppl 2):123–130

    PubMed  Google Scholar 

  79. Vellenga E, de Wolf JT, Halie MR (1989) Recombinant erythropoietin failed to correct anemia in Fanconi syndrome. Leukemia 3:858

    PubMed  CAS  Google Scholar 

  80. Bessho M, Hirashima K, Asano S et al (1997) Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony-stimulating factor: a multicenter randomized controlled study. Multicenter study group. Eur J Haematol 58:265–272

    PubMed  CAS  Google Scholar 

  81. Shao Z, Chu Y, Zhang Y, Chen G, Zheng Y (1998) Treatment of severe aplastic anemia with an immunosuppressive agent plus recombinant human granulocyte–macrophage colony-stimulating factor and erythropoietin. Am J Hematol 59:185–191

    Article  PubMed  CAS  Google Scholar 

  82. Boschetti C, Fermo E, Bianchi P, Vercellati C, Barraco F, Zanella A (2004) Clinical and molecular aspects of 23 patients affected by paroxysmal nocturnal hemoglobinuria. Am J Hematol 77:36–44

    Article  PubMed  CAS  Google Scholar 

  83. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW (1993) Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 328:73–80

    Article  PubMed  CAS  Google Scholar 

  84. al Khatti A, Umemura T, Clow J et al (1988) Erythropoietin stimulates F-reticulocyte formation in sickle cell anemia. Trans Assoc Am Physicians 101:54–61

    PubMed  Google Scholar 

  85. Nagel RL, Vichinsky E, Shah M et al (1993) F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood 81:9–14

    PubMed  CAS  Google Scholar 

  86. Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF (1990) Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 323:366–372

    Article  PubMed  CAS  Google Scholar 

  87. Rachmilewitz EA, Aker M, Perry D, Dover G (1995) Sustained increase in haemoglobin and RBC following long-term administration of recombinant human erythropoietin to patients with homozygous beta-thalassaemia. Br J Haematol 90:341–345

    PubMed  CAS  Google Scholar 

  88. Nisli G, Kavakli K, Aydinok Y, Oztop S, Cetingul N, Basak N (1997) Recombinant erythropoietin trial in children with transfusion-dependent homozygous beta-thalassemia. Acta Haematol 98:199–203

    Article  PubMed  CAS  Google Scholar 

  89. Chaidos A, Makis A, Hatzimichael E et al (2004) Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. Acta Haematol 111:189–195

    Article  PubMed  CAS  Google Scholar 

  90. Scientific discussion (2004) http://www.emea.eu.int/humandocs/Humans/EPAR/neorecormon/neorecormon.htm

  91. de Andrade JR, Jove M, Landon G, Frei D, Guilfoyle M, Young DC (1996) Baseline hemoglobin as a predictor of risk of transfusion and response to epoetin alfa in orthopedic surgery patients. Am J Orthop 25:533–542

    Article  PubMed  Google Scholar 

  92. Epoetin alfa–product approval information (2004) http://www.fda.gov/cder/foi/label/2004/103234_5053_Epogen_lbl.pdf

  93. Atabek U, Alvarez R, Pello MJ et al (1995) Erythropoetin accelerates hematocrit recovery in post-surgical anemia. Am Surg 61:74–77

    PubMed  CAS  Google Scholar 

  94. Corwin HL, Gettinger A, Rodriguez RM et al (1999) Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 27:2346–2350

    Article  PubMed  CAS  Google Scholar 

  95. Corwin HL, Gettinger A, Pearl RG et al (2002) Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 288:2827–2835

    Article  PubMed  CAS  Google Scholar 

  96. von Ahsen N, Muller C, Serke S, Frei U, Eckardt KU (1999) Important role of nondiagnostic blood loss and blunted erythropoietic response in the anemia of medical intensive care patients. Crit Care Med 27:2630–2639

    Article  PubMed  Google Scholar 

  97. Vincent JL, Baron JF, Reinhart K et al (2002) Anemia and blood transfusion in critically ill patients. JAMA 288:1499–1507

    Article  PubMed  Google Scholar 

  98. Silver DF, Piver MS (1999) Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 73:280–284

    Article  PubMed  CAS  Google Scholar 

  99. Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P (1998) Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 78:752–756

    PubMed  CAS  Google Scholar 

  100. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865–2874

    PubMed  CAS  Google Scholar 

  101. Bohlius J, Langensiepen S, Schwarzer G et al (2005) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97:489–498

    Article  PubMed  CAS  Google Scholar 

  102. Henke M, Laszig R, Rube C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260

    Article  PubMed  CAS  Google Scholar 

  103. Brower V (2003) Erythropoietin may impair, not improve, cancer survival. Nat Med 9:1439

    Article  PubMed  CAS  Google Scholar 

  104. Marchetti M, Barosi G (2004) Clinical and economic impact of epoetins in cancer care. Pharmacoeconomics 22:1029–1045

    Article  PubMed  CAS  Google Scholar 

  105. American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671–679

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Michael Heuser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heuser, M., Ganser, A. Recombinant human erythropoietin in the treatment of nonrenal anemia. Ann Hematol 85, 69–78 (2006). https://doi.org/10.1007/s00277-005-1086-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-1086-5

Keywords

Navigation